Achieve Life Sciences, Inc. (ACHV) fair value analysis
Nasdaq · Updated 2026-10-19
ACHV price how computed
Valuation status
No fair-value estimate yetACHV has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ACHV yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $6.38
- Sector
- Healthcare
- 12-month range
- $2.65–$8.53
- Market cap
- $658M
- From 52-week high
- -25.2%
- Shares outstanding
- 103M
- Rank in Healthcare by quality score
- #291 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Achieve Life Sciences, Inc. is a biopharmaceutical company that develops and commercializes therapeutic products focused on respiratory and other chronic diseases. The company operates in the United States and other markets, conducting research and development activities to advance its pipeline of drug candidates.
ACHV currently ranks #291 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $658M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-1.03
- Debt / equity
- 0.00
- Shares outstanding
- 103M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 28 · oversold
- 50-day average
- $7.58
- 200-day average
- $5.57
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 1 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-55.6%)
2026-03 ▲ beat (+36.7%)
2025-12 ▼ miss (-1.0%)
2025-09 ▼ miss (-7.7%)
2025-06 ▬ met (0.0%)
2025-03 ▬ met (0.0%)
2024-12 ▬ met (0.0%)
2024-09 ▼ miss (-24.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 0 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $14.2
- Target vs last price
- +122.6%
What our data shows for ACHV
- Shares are trading in the middle of their 12-month price range of $2.65–$8.53.
- The 14-day relative strength index sits at an oversold 28.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ACHV's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ACHV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for ACHV showed a shift this week as the RSI zone moved from neutral territory into oversold levels. The stock's valuation verdict remains under review as a full assessment is still being completed. This movement into oversold conditions may indicate that selling pressure has intensified in the Healthcare sector stock.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — ACHV's 50/200-day trend state shifted from uptrend to mixed this week, indicating a change in the stock's medium-term momentum trajectory. The company remains in the Healthcare sector with a valuation verdict currently awaiting full assessment.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ACHV stock undervalued?
TickrTrends has no fair-value estimate for ACHV yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ACHV's TickrTrends verdict?
ACHV is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ACHV compare to other Healthcare stocks?
ACHV ranks #291 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ACHV overbought or oversold?
ACHV's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does ACHV report earnings next?
ACHV's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does ACHV usually beat earnings estimates?
Over its last 8 reported quarters ACHV beat the consensus estimate 1 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ACHV?
Of 12 analysts covering ACHV, 12 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $14.2 (+122.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.